by Kevin Robb | Aug 22, 2024
Last month, the U.S. Food and Drug Administration (FDA) agreed to formally review a revised Biologics License Application (BLA) from Mesoblast for their mesenchymal stromal cell (MSC) product, remestemcel-L. The submission represents the third attempt by the company...
by Lyla El-Fayomi | Apr 4, 2024
Regenerative Medicine News Under the Microscope is back! Thank you all for your patience as I wrapped up my PhD; the hiatus is officially over. We’re celebrating the return of this feature with a double header covering regenerative medicine research highlights from...
by Laine Bodnar | Feb 29, 2024
In my role as a communication professional at CCRM, I have had the opportunity to attend industry conferences and events. There, I have met brilliant minds in the regenerative medicine and cell therapy field and learned about the work that’s happening in their...
by Francesco Zangari | Feb 7, 2024
In today’s fast-paced world, science, technology, engineering and mathematics (STEM) skills have never been more crucial for driving the innovation that modern societies demand. But, for many curious young minds, STEM can appear distant and confusing, with...
by Stacey Johnson | Dec 29, 2023
It’s been a busy year in the cell and gene therapy community and the bloggers at Signals have enjoyed putting the spotlight on news (HeLa settlement and UK rejoins Horizon Europe), scientific advances (improving treatment for hematological malignancies and a new...
by Kevin Robb | Nov 9, 2023
BlueRock Therapeutics has generated considerable media buzz with their announcement of positive Phase I clinical trial data on bemdaneprocel (BRT-DA01), an investigational, stem cell-derived, dopaminergic therapy for Parkinson’s disease. The trial is the result of...
Comments